Core Viewpoint - Guerbet has appointed Mr. Antoine Fady as a non-voting director, with plans for him to become Chairman, succeeding Mr. Hugues Lecat, who is stepping down for personal reasons [2][3][4]. Group 1: Appointment Details - Mr. Antoine Fady's appointment will be submitted for approval at the next Shareholders' Meeting, with the intention of him becoming Chairman after the meeting [3]. - The Board expressed confidence in Mr. Fady's experience in leading large industrial companies and his strategic vision, which are expected to support Guerbet's transformation and future achievements [4]. Group 2: Mr. Antoine Fady's Background - Mr. Fady is a trained engineer with an MBA from INSEAD and has over ten years of experience as CEO of Flint Group, where he led significant strategic transformations [6]. - He has held various general management roles at ICI and Akzo Nobel, particularly in the paints and coatings sectors in Europe, and has governance experience as a non-executive director and board chairman at Roquette and XSYS [7][8]. Group 3: Company Overview - Guerbet is a global leader in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions, with a focus on innovation and R&D, dedicating 10.3% of its revenue to these efforts [10]. - The company achieved €786 million in revenue in 2025 and has a workforce of 2,746 employees worldwide [10].

Group 1 - Guerbet has appointed Mr. Karim Boussebaa as Chief Executive Officer, effective February 2, 2026, following a decision by the Board of Directors [2][4] - Mr. Boussebaa has over 25 years of international experience in healthcare and medical technology, with a strong background in medical imaging and medical devices [3] - The appointment aims to strengthen Guerbet's operational and strategic management to adapt to a rapidly evolving market environment [4] Group 2 - Mr. Hugues Lecat, Chairman of the Board, emphasized the importance of Mr. Boussebaa's leadership in supporting the company's strategy and performance [4] - Mr. Jérôme Estampes will return to his role as Group Chief Financial Officer and SVP Business Development & Licensing after serving as interim CEO [5] - Guerbet reported €841 million in revenue for 2024 and dedicates 9% of its revenue to Research & Development [7]

Core Viewpoint - Guerbet has announced a downward revision of its financial targets for the full year 2025 due to compliance issues following an FDA inspection, which has led to delays in production and expected revenue losses [2][4][5]. Financial Impact - The company anticipates a revenue decrease of between -4% and -5% at constant exchange rates, compared to a previously announced slight decrease of -1% [9]. - The restated EBITDA margin is now expected to be between 10.5% and 12% of revenue, down from the previously announced range of 12% to 13% [9]. - Free cash flow is projected to be between -5 million euros and -15 million euros, compared to a previously expected slightly negative figure [9]. Compliance and Regulatory Actions - Following the FDA inspection, Guerbet has developed and initiated a compliance plan at its Raleigh site, which has been reinforced in response to FDA observations [3][4]. - The implementation of this compliance plan has delayed the release of manufactured batches, leading to anticipated revenue losses for the 2025 financial year [4][5]. Company Overview - Guerbet is a global leader in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions, with a commitment to innovation and a significant investment in Research and Development [6]. - The company generated revenue of €841 million in 2024 and employs over 2,905 people worldwide [6].

Core Viewpoint - Guerbet has appointed Mr. Jérôme Estampes as interim Chief Executive Officer, succeeding Mr. David Hale, who is leaving the company to pursue new projects [2][3]. Company Management Changes - Mr. Jérôme Estampes has been with Guerbet since 2019 as Chief Administrative and Financial Officer, where he has developed a strong understanding of the company's financial, operational, and commercial challenges [3]. - The Board of Directors has expressed gratitude to Mr. David Hale for his contributions since joining in February 2018, first as Chief Commercial Officer and then as CEO from January 1, 2020 [2][4]. Transition and Future Leadership - The Board supports Mr. Estampes and he will have the assistance of Guerbet's Executive Committee to ensure a smooth transition and to continue implementing transformation measures and the commercial strategy [4]. - The Nominations and Remuneration Committee has initiated the recruitment process for a permanent Chief Executive Officer [4]. Company Overview - Guerbet is a global leader in medical imaging, focusing on improving patient care through innovation, with nearly a century of expertise [6]. - The company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging [6]. - Guerbet invests 10% of its annual revenue in research and development and reported €786 million in revenue in 2023 [6].